- Home
- MET vs TAK Comparison
MET vs TAK Comparison
Compare MET & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MET | TAK |
|---|---|---|
| Founded | 1863 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4B | 59.8B |
| IPO Year | 1999 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MET | TAK |
|---|---|---|
| Price | $102.17 | $21.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 3 |
| Target Price | ★ $110.63 | $22.74 |
| AVG Volume (30 Days) | 3.0M | ★ 3.0M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.30% | 1.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.48 | N/A |
| Revenue | ★ $77,084,000,000.00 | N/A |
| Revenue This Year | $3.11 | $4.54 |
| Revenue Next Year | $4.57 | $2.37 |
| P/E Ratio | ★ $15.87 | $41.25 |
| Revenue Growth | ★ 8.59 | N/A |
| 52 Week Low | $67.33 | $13.91 |
| 52 Week High | $106.72 | $21.73 |
Technical Indicators
Market Signals| Indicator | MET | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 67.19 |
| Support Level | $92.95 | $17.73 |
| Resistance Level | $103.65 | $21.73 |
| Average True Range (ATR) | 2.23 | 0.37 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 49.89 | 74.83 |
Price Performance
Historical ComparisonAbout MET MetLife Inc.
MetLife is one of the largest life insurers in the US by assets and provides a variety of life insurance and annuity products. It is organized into six segments: group benefits, retirement and income solutions, Asia, Latin America, Europe/Middle East/Africa (EMEA), and MetLife Investment Managenent. Group Benefits and RIS are US-based, contributing to around 52% of the firm's 2025 adjusted earnings. The Asia segment contributes around 25% of earnings, mainly tied to Japan. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 14% of 2024 earnings. The EMEA and investment management segments contributed around 6% and 3% of 2025 earnings, respectively.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.